IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients

The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma

(2010) Fonnet E. Bleeker et al.   ACTA NEUROPATHOLOGICA

R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma

(2010) Susan C. Williams et al.   ACTA NEUROPATHOLOGICA

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

(2010) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis

(2010) Philippe Metellus et al.   ACTA NEUROPATHOLOGICA

Glioma-derived mutations in IDH: From mechanism to potential therapy

(2010) Yuejun Fu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

IDH1 Mutations in Gliomas: When an Enzyme Loses Its Grip

(2010) Christian Frezza et al.   CANCER CELL

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

(2010) Patrick S. Ward et al.   CANCER CELL

IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

(2010) M. J. van den Bent et al.   CLINICAL CANCER RESEARCH

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

(2010) Stefan Gross et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism

(2010) Z. J. Reitman et al.   JNCI-Journal of the National Cancer Institute

Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?

(2010) Nanne K Kloosterhof et al.   LANCET ONCOLOGY

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Antitumor effects of 2-oxoglutarate through inhibition of angiogenesis in a murine tumor model

(2009) Ken Matsumoto et al.   CANCER SCIENCE

IDH1mutations at residue p.R132 (IDH1R132) occur frequently in high-grade gliomas but not in other solid tumors

(2009) Fonnet E. Bleeker et al.   HUMAN MUTATION

Neuronal apoptosis by prolyl hydroxylation: implication in nervous system tumours and the Warburg conundrum

(2009) Susanne Schlisio   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome

(2009) Elaine R. Mardis et al.   NEW ENGLAND JOURNAL OF MEDICINE

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1 

(2009) S. Zhao et al.   SCIENCE

Analysis of the IDH1 codon 132 mutation in brain tumors

(2008) Jörg Balss et al.   ACTA NEUROPATHOLOGICA

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE